192 related articles for article (PubMed ID: 11736859)
1. Population pharmacokinetics and pharmacodynamics of oral etoposide.
Toffoli G; Corona G; Sorio R; Robieux I; Basso B; Colussi AM; Boiocchi M
Br J Clin Pharmacol; 2001 Nov; 52(5):511-9. PubMed ID: 11736859
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of chronic oral etoposide in patients with small cell and non-small cell lung cancer.
Zucchetti M; Pagani O; Torri V; Sessa C; D'Incalci M; De Fusco M; de Jong J; Gentili D; Martinelli G; Tinazzi A
Clin Cancer Res; 1995 Dec; 1(12):1517-24. PubMed ID: 9815952
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer.
Millward MJ; Newell DR; Yuen K; Matthews JP; Balmanno K; Charlton CJ; Gumbrell L; Lind MJ; Chapman F; Proctor M
Cancer Chemother Pharmacol; 1995; 37(1-2):161-7. PubMed ID: 7497587
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation of treatment with oral etoposide.
Toffoli G; Corona G; Basso B; Boiocchi M
Clin Pharmacokinet; 2004; 43(7):441-66. PubMed ID: 15139794
[TBL] [Abstract][Full Text] [Related]
6. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
[TBL] [Abstract][Full Text] [Related]
7. Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.
You B; Tranchand B; Girard P; Falandry C; Ribba B; Chabaud S; Souquet PJ; Court-Fortune I; Trillet-Lenoir V; Fournel C; Tod M; Freyer G
Lung Cancer; 2008 Nov; 62(2):261-72. PubMed ID: 18442869
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of total and unbound etoposide.
Nguyen L; Chatelut E; Chevreau C; Tranchand B; Lochon I; Bachaud JM; Pujol A; Houin G; Bugat R; Canal P
Cancer Chemother Pharmacol; 1998; 41(2):125-32. PubMed ID: 9443625
[TBL] [Abstract][Full Text] [Related]
9. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
10. Predicting etoposide toxicity: relationship to organ function and protein binding.
Joel SP; Shah R; Clark PI; Slevin ML
J Clin Oncol; 1996 Jan; 14(1):257-67. PubMed ID: 8558207
[TBL] [Abstract][Full Text] [Related]
11. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring of 21-day oral etoposide in patients with advanced non-small cell lung cancer.
Miller AA; Tolley EA; Niell HB
Clin Cancer Res; 1998 Jul; 4(7):1705-10. PubMed ID: 9676845
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
14. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors.
Marty M; Fumoleau P; Adenis A; Rousseau Y; Merrouche Y; Robinet G; Senac I; Puozzo C
Ann Oncol; 2001 Nov; 12(11):1643-9. PubMed ID: 11822766
[TBL] [Abstract][Full Text] [Related]
15. Inter- and intrapatient variability in etoposide kinetics with oral and intravenous drug administration.
Hande K; Messenger M; Wagner J; Krozely M; Kaul S
Clin Cancer Res; 1999 Oct; 5(10):2742-7. PubMed ID: 10537337
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological analysis of etoposide in elderly patients with lung cancer.
Ando M; Minami H; Ando Y; Sakai S; Shimono Y; Sugiura S; Saka H; Shimokata K; Hasegawa Y
Clin Cancer Res; 1999 Jul; 5(7):1690-5. PubMed ID: 10430070
[TBL] [Abstract][Full Text] [Related]
17. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
18. Oral etoposide in patients with hematological malignancies: a clinical and pharmacokinetic study.
Osby E; Liliemark E; Björkholm M; Liliemark J
Med Oncol; 2001; 18(4):269-75. PubMed ID: 11918453
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
Yong WP; Desai AA; Innocenti F; Ramirez J; Shepard D; Kobayashi K; House L; Fleming GF; Vogelzang NJ; Schilsky RL; Ratain MJ
Cancer Chemother Pharmacol; 2007 Nov; 60(6):811-9. PubMed ID: 17308893
[TBL] [Abstract][Full Text] [Related]
20. Effect of grapefruit juice intake on etoposide bioavailability.
Reif S; Nicolson MC; Bisset D; Reid M; Kloft C; Jaehde U; McLeod HL
Eur J Clin Pharmacol; 2002 Oct; 58(7):491-4. PubMed ID: 12389073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
